AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 60 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $625 | +55.5% | 1,391,381 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $402 | -35.7% | 1,391,381 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $625 | -99.7% | 1,391,381 | +196.9% | 0.00% | +200.0% |
| Q3 2022 | $245,000 | +17.8% | 468,558 | +13.3% | 0.00% | 0.0% |
| Q2 2022 | $208,000 | -39.2% | 413,387 | +176.7% | 0.00% | 0.0% |
| Q1 2022 | $342,000 | -44.8% | 149,399 | +14.2% | 0.00% | -50.0% |
| Q4 2021 | $620,000 | +798.6% | 130,835 | +1426.7% | 0.00% | – |
| Q1 2019 | $69,000 | -86.7% | 8,570 | -84.2% | 0.00% | -100.0% |
| Q3 2018 | $519,000 | -32.9% | 54,230 | -25.8% | 0.00% | -33.3% |
| Q2 2018 | $773,000 | +151.8% | 73,100 | +136.9% | 0.00% | +200.0% |
| Q1 2018 | $307,000 | +468.5% | 30,860 | +206.4% | 0.00% | – |
| Q4 2017 | $54,000 | +145.5% | 10,073 | +121.2% | 0.00% | – |
| Q3 2017 | $22,000 | +1000.0% | 4,554 | +840.9% | 0.00% | – |
| Q4 2016 | $2,000 | – | 484 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |